@article{dd04809f1dcd4f19a0518b45ee89e238,
title = "Pneumococcal conjugate vaccines in Taiwan: optimizing health gains in children and older adults through constrained optimization modeling: Pneumococcal conjugate vaccines optimization in Taiwan",
abstract = "Objectives: Budgetary constraints force healthcare authorities to set priorities for optimal vaccine interventions. A comprehensive decision-making tool would help inform the best combination and sequence of introduction of vaccines within constrained budgets. Methods: Looking at available vaccines against pneumococcal infections in Taiwan (10/13-valent pneumococcal conjugate vaccines [PCV10, PCV13] and 23-valent pneumococcal polysaccharide vaccine [PPV23]), a constrained optimization (CO) model was used to assess the optimal combination of vaccines in children and older adults that would maximize the quality-adjusted life years under predefined budget constraints. Scenario analyses were carried out to evaluate the impact of vaccine efficacy (VE) on the optimized solution. Results: The CO model demonstrated that the optimal sequence of vaccine introduction was PPV23 in older adults and PCV10 in children. The optimal solution was mostly driven by the potential to reduce disease burden in the older adult population. The VE of PPV23 in older adults and the VE of PCV vaccines against serotype 19A invasive pneumococcal disease had little impact on the optimal solution. Conclusions: The CO approach can be used to set priorities for introducing new vaccines while maximizing health gains per age group within the constrained National Vaccine Fund for the prevention of pneumococcal disease in Taiwan.",
keywords = "constrained optimization model, pneumococcal disease, public health, Taiwan, vaccine",
author = "Lu, {Chun Yi} and Tang, {Chao Hsiun} and Tiffany Fu and Pwu, {Raoh Fang} and Ho, {Yu Fan}",
note = "Funding Information: In Taiwan, vaccines administered as a part of the National Immunization Program (NIP) are funded through the National Vaccine Fund (NVF), which is mainly financed through proceeds from the tobacco sales surcharge (65%), with the remainder coming from the governmental budget. From 2015 onwards, this additional source of revenue helped the introduction of new vaccines in the NIP, including the 13-valent pneumococcal conjugate vaccination (PCV13) for children. However, the revenue collected from the surcharge is not stable, and the NVF has to compete with other healthcare initiatives ( Taiwan Centers for Disease Control, 2019a ). Funding Information: GlaxoSmithKline Biologicals SA funded this study (study identifier: HO-19-19828) and was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also covered all the costs associated with the development and publication of this manuscript. This report is based on a study using an economic model and input data collected from the literature and publicly available databases. The study did not involve any interventions with human participants or animals. Hence, no ethical approval was requested. CYL, CHT, and TF participated in the study design and data collection, and in the generation, analysis, and interpretation of the results. RFP participated in the interpretation of the study. YFH led the development of the manuscript and participated in the interpretation of data. All authors participated in the development of this manuscript, had full access to the data, and gave final approval prior to submission. All authors would like to thank Jan Olbrecht, Chanelle Owen, and Sumitra Shantakumar for their critical review of the manuscript. The authors would also like to thank Business and Decision Life Sciences platform for editorial assistance and manuscript coordination, on behalf of GSK. Janne Tys coordinated the manuscript development and editorial support, and Katrin Spiegel provided writing support. Publisher Copyright: {\textcopyright} 2021 GlaxoSmithKline Biologicals S.A.",
year = "2022",
month = jan,
doi = "10.1016/j.ijid.2021.10.058",
language = "English",
volume = "114",
pages = "155--164",
journal = "International Journal of Infectious Diseases",
issn = "1201-9712",
publisher = "Elsevier",
}